# A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct03914326` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03914326](<https://clinicaltrials.gov/study/NCT03914326>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03914326

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9651 participants.

## Technical summary

Registry record NCT03914326. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2024-08-23 (actual). Results posted on 2025-09-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 9651 participants (enrolled count; ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Started: 2019-06-17 (actual) (ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Primary completion: 2024-08-23 (actual) (ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Completion: 2024-08-23 (actual) (ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Results first posted: 2025-09-22 (ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Countries: United States; Algeria; Argentina; Austria; Belgium; Brazil; Canada; China; Colombia; Croatia; Czechia; Denmark; France; Germany; Hong Kong SAR China; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Romania; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03914326, source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03914326-2025-12-11`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- Acronym: SOUL
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (`cardio:pubmed-40162642`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (`cardio:pubmed-40156843`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (`cardio:pubmed-41380027`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (`cardio:pubmed-41627802`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial (`cardio:pubmed-41879791`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 15d016496adbee58826826543b8e9c75aff8ca6239423e68e455f6cfa2ae92af
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
